Bayer/Exiligis partnership yields novel insecticides
Scientists at Exelixis, Inc. have announced that their joint venture with Bayer's crop protection business group, Genoptera LLC, has delivered several additional novel insecticide targets for development. The targets were developed using Exelixis' genomics-based technology, marking a new approach that uses genetic information to target pests.
"We are extremely satisfied to see that Genoptera continues to deliver on its challenging objectives," said Geoff Duyk M.D., Ph.D., chief scientific officer of Exelixis. "Through Genoptera, we are proving that our expertise in model system genetics and comparative genomics adds substantial value to research for crop protection chemicals by providing unique new targets."
Formed in January 2000, Genoptera LLC focuses on the discovery of novel insecticides and nematicides. The joint venture is a continuation and expansion of the collaboration that Exelixis and Bayer initially established in April 1998 and expanded in June 1999. In addition to $80 million in committed research funding over the course of the eight-year joint venture, the arrangement involves a $20 million up-front payment and performance-based milestone and royalty payments to Exelixis. Bayer has the exclusive right to commercialize insecticides based on technology developed by Genoptera.
For more information, visit Exelixis' web site at www.exelixis.com.